Allezoe Medical Holdings, Inc.
OTC Bulletin Board : ALZM

Allezoe Medical Holdings, Inc.

September 23, 2011 12:29 ET

Allezoe Medical Holdings (ALZM) Moving Forward With Global Strategy For New HPV Diagnostic Technology

$18B Diagnostic Market "Just the tip of the iceberg" Says CEO

BOCA RATON, FLORIDA--(Marketwire - Sept. 23, 2011) - Allezoe Medical Holdings, Inc. (OTCBB:ALZM) announces today its intention of carrying out a global rollout of its HPV diagnostic technology. Earlier this week Allezoe announced that is in the process of acquiring "see and treat" technology for Human Papillomavirus (HPV), the leading sexually transmitted infection, and a major cause of cervical cancer in women around the world. Screening for cervical cancer and its precursors (including HPV) remains the top strategy for cancer prevention.

In the United States alone, there is a $6B diagnosis and treatment market for HPV (primary screening alone is over $2B). While the American market for such technology is strong, Allezoe's strategy takes into account the immense market opportunity for the technology abroad.

An estimated 20 Million American women ages 15 and over are infected with HPV, with millions of new cases diagnosed each year. Around the world, the number multiplies exponentially: 233 million women ages 15 and over are infected with HPV. As a result, an $18B diagnosis and treatment market exists worldwide – yet this is with only a 10% test rate.

CEO of Allezoe Michael Gelmon says "If only 10% of people are being tested for HPV, the world needs a screening system that more people will use. The market appeal of our technology lies in the fact that it's thorough [98% accuracy], but it's convenient and inexpensive. That difference is what will allow us to become the standard for medical offices in Los Angeles as easily as villages in South America, Africa, and throughout the world."

Allezoe also believes its technology will appeal to the World Health Organization. The World Health Organization's (WHO) International Agency for Research on Cancer has stated that "There is a need to develop simple, affordable and accurate methods of HPV testing with comprehensive guidelines for its use in screening programmes." The "SureScreen™" technology and processes Allezoe will be acquiring is all of the above.

In addition to cervical cancer, which is considered "preventable" with proper screening, HPV has been identified as the cause of a wide range of other cancers in both men and women. Allezoe is preparing to launch a wholly-owned subsidiary to house the patent pending application and related intellectual property it is acquiring. That subsidiary will see the technology through regulatory processes and its worldwide market launch.

Gelmon says, "The future of STI testing is about to change."

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated. These risks are set forth in the Company's most recently filed form 10-K and Form 10-Q reports. The Company assumes no obligation to update the statements contained in this release except as required by applicable securities disclosure rules. The Company's SEC filings are available at

Contact Information